PROTAC ERRα Degrader-1
Based on 1 Customer Validation
PROTAC ERRα Degrader-1 comprises a MDM2 ligand binding group, a linker and an estrogen-related receptor alpha (ERRa) binding group. PROTAC ERRα Degrader-1 is an PROTAC estrogen-related receptor alpha (ERRa) degrader.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 98.22%
- No. CAS: 2306388-84-9
- Fòrmula: C54H49Cl2F6N7O8
- Peso molecular:1108.91
-
Almacenamiento:
-20°C, stored under nitrogen, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-13757A
TamoxifenEstrogen Receptor Modulator -
HY-13757AR
Tamoxifen (Standard)Estrogen Receptor Modulator -
HY-128600
ERD-308ER PROTAC Degrader -
HY-128527
PROTAC ER Degrader-3PROTAC ER Degrader -
HY-112098
PROTAC ERα Degrader-1PROTAC ERα Degrader -
HY-128839
PROTAC ERRα Degrader-2PROTAC ERRα Degrader
Ver todos los productos específicos de isoformas PROTACs
More
Actividad biológica
Descripciòn
IC50 & Target
|
ERRα |
MDM2 |
Chemical Information
-
No. CAS 2306388-84-9
-
Appearance Solid
-
Peso molecular 1108.91
-
Fòrmula C54H49Cl2F6N7O8
-
Color White to off-white
-
SMILES
O=C(N1CC(N(CC(NCCNC(/C(C#N)=C/C2=CC(OC)=C(OCC3=C(C=C(C(F)(F)F)C=C3)C(F)(F)F)C=C2)=O)=O)CC1)=O)N4[C@@H](C5=CC=C(Cl)C=C5)[C@@H](C6=CC=C(Cl)C=C6)N=C4C7=C(C=C(OC)C=C7)OC(C)C
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
-20°C, stored under nitrogen, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)
Solvente y solubilidad
In Vitro:
DMSO : 100 mg/mL (90.18 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (2.25 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocolo
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
Pureza y Documentación
-
Ficha de datos (272 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.9018 mL | 4.5089 mL | 9.0179 mL | 22.5447 mL |
| 5 mM | 0.1804 mL | 0.9018 mL | 1.8036 mL | 4.5089 mL | |
| 10 mM | 0.0902 mL | 0.4509 mL | 0.9018 mL | 2.2545 mL | |
| 15 mM | 0.0601 mL | 0.3006 mL | 0.6012 mL | 1.5030 mL | |
| 20 mM | 0.0451 mL | 0.2254 mL | 0.4509 mL | 1.1272 mL | |
| 25 mM | 0.0361 mL | 0.1804 mL | 0.3607 mL | 0.9018 mL | |
| 30 mM | 0.0301 mL | 0.1503 mL | 0.3006 mL | 0.7515 mL | |
| 40 mM | 0.0225 mL | 0.1127 mL | 0.2254 mL | 0.5636 mL | |
| 50 mM | 0.0180 mL | 0.0902 mL | 0.1804 mL | 0.4509 mL | |
| 60 mM | 0.0150 mL | 0.0751 mL | 0.1503 mL | 0.3757 mL | |
| 80 mM | 0.0113 mL | 0.0564 mL | 0.1127 mL | 0.2818 mL |
PROTAC ERRα Degrader-1 Related Classifications
HY-128838 Related Classifications
Powered by Bioz